Formela Jean Francois Sells Shares of Korro Bio, Inc.

Formela Jean Francois sold 48,438 shares of Korro Bio, Inc. (NasdaqCM: KRRO) on June 24, 2026. The transaction was planned and executed at an average price of $14.61 per share, totaling approximately $707,490.27.

Insider Buying and Selling at Korro Bio, Inc.

Formela Jean Francois was active in selling shares of Korro Bio over several days. On June 23, 2026, he sold 119,005 shares at $14.25 each, and on June 22, 2026, he sold 3,962 shares at $13.95 each. These sales were also part of planned transactions. Additionally, on June 16, 2026, Jeffrey Cerio, General Counsel, sold 6,609 shares at $10.83, and Oliver Dolan, Senior Vice President of Finance, sold 3,383 shares at the same price. Loic Vincent, Chief Scientific Officer, also sold 3,418 shares on that day.

Other Institutional Activity in Korro Bio

Several institutional investors have also been adjusting their positions in Korro Bio. LYNX1 Capital Management LP increased its holdings by 860,381 shares, bringing its total to 1,538,296 shares valued at approximately $17.4 million, marking a 126.9% increase. NEA Management Company, LLC added 207,100 shares, ending with 1,297,893 shares worth about $14.7 million, a 19% increase. Atlas Venture Life Science Advisors, LLC maintained its position with 1,137,149 shares valued at $12.9 million. New positions were opened by Balyasny Asset Management L.P. and Venrock Adviser, LLC, each with over 1 million shares.

Korro Bio, Inc. Stock Up 6.7%

Shares of Korro Bio traded near $13.77 on Thursday. The company has a market capitalization of around $200.5 million and a forward P/E ratio of -2.76, indicating it is not currently profitable. The stock has a 52-week low of $5.20 and a high of $55.89, with a 50-day moving average of $12.20 and a 200-day moving average of $17.71. Korro Bio's beta is 2.096, reflecting higher volatility compared to the market. The company's current ratio is 8.13, showing strong liquidity, while the debt-to-equity ratio stands at 35.85.

Analysts Set New Price Targets

Analysts have been active in setting new price targets for Korro Bio. On May 19, 2026, HC Wainwright & Co. maintained a 'buy' rating with a $15 target. On May 18, 2026, Citigroup initiated coverage with a 'buy' rating and a $21 target. In March 2026, Cantor Fitzgerald and Raymond James both maintained 'buy' ratings with targets of $22 and $23, respectively. The consensus target is $20, based on 10 analyst opinions.

About Korro Bio, Inc.

Korro Bio, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing genetic medicines using RNA editing technology. The company's lead candidate, KRRO-121, targets hyperammonemia. Korro Bio also explores treatments for Parkinson's disease, ALS, and pain management. Founded in 2018, the company collaborates with Novo Nordisk on cardiometabolic diseases.

Bottom Line

The recent insider sales by Formela Jean Francois are part of planned transactions, indicating strategic personal financial management. Korro Bio's stock remains a focal point for investors due to its innovative RNA editing platform and collaborations. Institutional activity and analyst ratings reflect ongoing interest in the company's growth potential. As always, the data from these filings is historical and may not represent current positions.